Briacell Therapeutics

Yahoo Finance • 2 months ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

PHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunoth... Full story

Yahoo Finance • 4 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVIDBriaCell’s Phase 3 clinical trial in metastatic br... Full story

Yahoo Finance • 5 months ago

BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Over 230 patients screened and over 160 patients enrolled in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC)Enrollment exceeding expectations with strong clinical site and patient interestTopline interim data readout exp... Full story

Yahoo Finance • 5 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Three poster presentations at the San Antonio Breast Cancer Symposium (SABCS), now available and to be presented on December 10, 2025, highlight robust survival and clinical benefit data in Phase 2, plus positive key biomarker data from th... Full story

Yahoo Finance • 5 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight positive Phase 2 safety and efficacy signals and positive biomarker findings in both the Phase 2 and the pivotal Phase 3 studies The p... Full story

Yahoo Finance • 5 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Three BriaCell poster presentations include updated key biomarker data from BriaCell’s pivotal Phase 3 study and updated survival data from the Phase 2 study of Bria-IMT™ plus immune check point inhibitor (CPI) in metastatic breast cancer... Full story

Yahoo Finance • 6 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Next generation Bria-OTS+ platform demonstrates rapid, potent and durable anti-cancer activity by activating both innate and adaptive immune responses Increased tumor cell cytotoxicity induced by both Bria-BRES+™ (breast cancer) and Bria-P... Full story

Yahoo Finance • 6 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitorFourth consecutive positive DSMB recommendation supports the favorable safety... Full story

Yahoo Finance • 6 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

79 clinical sites across 23 US states are currently enrolling patients in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC) Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer Institute of Emory Univer... Full story

Yahoo Finance • 6 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ platform, which includes Bria-BRES+™ for breast cancer PHILADELPHIA and VANCOUVER, British Columbia,... Full story

Yahoo Finance • 6 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Biomarkers identified in BriaCell’s Phase 2 study are showing similar and encouraging trends in the ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic breast cancer (MBC)No new safety or tolerability issues identified in pooled analy... Full story

Yahoo Finance • 7 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Biomarkers identified in Phase 2 study demonstrate similar trends in ongoing pivotal Phase 3 study of Bria-IMT™ in metastatic breast cancer (MBC)Positive delayed-type hypersensitivity (DTH) – a potential biomarker predictive of improved cl... Full story

Yahoo Finance • 8 months ago

BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Data from BriaCell and the US National Cancer Institute (NCI) support the cancer cell killing potential of BriaCell’s Bria-OTS+ platformBria-OTS+, a novel personalized,off-the-shelf, semi-allogeneic cellular immunotherapy may address urgen... Full story

Yahoo Finance • 8 months ago

BriaCell to implement 1-for-10 reverse stock split to maintain Nasdaq listing

* BriaCell Therapeutics (NASDAQ:BCTX [https://seekingalpha.com/symbol/BCTX]) will consolidate its common shares on a 1-for-10 basis to meet Nasdaq listing requirements. * The reverse split is expected to become effective on August 25,... Full story

Yahoo Finance • 8 months ago

BriaCell Announces Proposed Effective Date of Share Consolidation

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel... Full story

Yahoo Finance • 9 months ago

BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops nove... Full story

Yahoo Finance • 9 months ago

UCLA Health joins BriaCell's phase 3 breast cancer study

PHILADELPHIA/VANCOUVER - BriaCell Therapeutics Corp. (NASDAQ:BCTX, TSX: BCT), a clinical-stage biotechnology company with a market capitalization of $2.5 million and an overall "WEAK" InvestingPro Financial Health score of 1.36, announced... Full story

Yahoo Finance • 9 months ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

PHILADELPHIA and VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel im... Full story

Yahoo Finance • 9 months ago

BriaCell granted New Zealand patent for cancer immunotherapy method

PHILADELPHIA/VANCOUVER - BriaCell Therapeutics Corp. (NASDAQ:BCTX, TSX:BCT), a micro-cap biotechnology company with a market value of $2.5 million, announced Wednesday it has been granted New Zealand Patent No. 785587 for its whole-cell ca... Full story

Yahoo Finance • 9 months ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

PHILADELPHIA and VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel im... Full story